<http://webisa.webdatacommons.org/prov/246059898>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/420744702> .
<http://webisa.webdatacommons.org/prov/503844212>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/420744702> .
<http://webisa.webdatacommons.org/420744702>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/prov#Entity> .
<http://webisa.webdatacommons.org/420744702>	<http://www.w3.org/ns/prov#wasQuotedFrom>	<seekingalpha.com> .
<http://webisa.webdatacommons.org/420744702>	<http://www.w3.org/ns/prov#value>	"We currently have more than 20 new compounds or indications in Phase II or III development across oncology, immunology, HCV, neuroscience and pain management and other areas of significant medical need." .
<http://webisa.webdatacommons.org/prov/408499022>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/420744702> .